Trial · NCT05283304
Monthly Injectable BUP for MA Use Disorder (MURB) Trial
NCT05283304, Phase 2, Terminated, Madhukar H. Trivedi, MD; results first posted 2025-03-21
3 sourcestrials-2026-11-12-0.4.0
Download JSON
Cite this record
ConductScience Library. Monthly Injectable BUP for MA Use Disorder (MURB) Trial. Trials, record NCT05283304. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05283304
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Monthly Injectable BUP for MA Use Disorder (MURB) Trial
- NCT number
- NCT05283304
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 18 participants, actual
- Lead sponsor
- Madhukar H. Trivedi, MD
- Conditions
- Methamphetamine-dependence
- Interventions
- Buprenorphine injection (BUP-Inj), Placebo injection
- First posted
- 2022-03-16
- Last updated
- 2025-03-21
- Results first posted
- 2025-03-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Methamphetamine-negative Urine Samples | weeks 9-12 | Number of Methamphetamine (MA)-negative Urine Drug Screen (UDS) results obtained during Weeks 9 through 12 of the medication phase is measured for the BUP-Inj and PBO-Inj conditions. Number of UDS results / number of expected UDS results. Two UDS results were expected each week. |
| Secondary | Treatment Effective Score (TES) for MA-negative UDS Results | weeks 1-12 | The TES is defined to be the number of MA negative UDS divided by the number of possible UDS collected during the study. In this study there are 24 possible UDS collections so the number of MA negative UDS is divided by 24. Possible score ranges from 0-24; with higher score indicating better outcome. |
| Secondary | Number of Days of Methamphetamine Use During the Medication Phase | weeks 1-12 | Number of days of methamphetamine use during treatment will be measured using Timeline Followback (TLFB) procedure which will be administered to document the participant's self-reported use during Weeks 1-12. Possible scores range from 0-84, with lower scores indicating better outcome. |
| Secondary | Treatment Effective Score (TES) for Opioid Negative UDS Results | weeks 1-12 | The TES is defined to be the number of UDS results negative for opioids divided by the number of possible UDS collected during the study. In this study there are 24 possible UDS collections, so the number of opioid negative UDS is divided by 24. Possible score ranges from 0-24; with higher score indicating better outcome. |
| Secondary | Number of Days of Opioid Use During the Medication Phase | weeks 1-12 | Number of days of opioid use during treatment will be measured using Timeline Followback (TLFB) procedure which will be administered to document the participant's self-reported opioid use at week 12. Possible scores range from 0-84, with lower scores indicating better outcome. |
| Secondary | Treatment Effective Score (TES) for MA and Opioid Co-Use Compiled | weeks 1-12 | The TES is defined to be the number of MA and Opioid Co-Use negative UDS divided by the number of possible UDS collected during the study. In this study there are 24 possible UDS collections, so the number of MA and Opioid Co-Use negative UDS is divided by 24. Possible score ranges from 0-24; with higher score indicating better outcome. |
| Secondary | Number of Days of MA and Opioid Co-use During the Medication Phase | weeks 1-12 | Number of days of MA and opioid co-use during treatment will be measured using Timeline Followback (TLFB) procedure which will be administered to document the participant's self-reported use of substances for each day at week 12. Possible scores range from 0-84, with lower scores indicating better outcome. |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Methamphetamine-negative Urine Samples | weeks 9-12 | urine samples | COUNT_OF_UNITS | |
| SECONDARY | Treatment Effective Score (TES) for MA-negative UDS Results | weeks 1-12 | score on a scale | MEDIAN | |
| SECONDARY | Number of Days of Methamphetamine Use During the Medication Phase | weeks 1-12 | days | MEAN | |
| SECONDARY | Treatment Effective Score (TES) for Opioid Negative UDS Results | weeks 1-12 | score on a scale | MEDIAN | |
| SECONDARY | Number of Days of Opioid Use During the Medication Phase | weeks 1-12 | days | MEAN | |
| SECONDARY | Treatment Effective Score (TES) for MA and Opioid Co-Use Compiled | weeks 1-12 | score on a scale | MEDIAN | |
| SECONDARY | Number of Days of MA and Opioid Co-use During the Medication Phase | weeks 1-12 | days | MEAN |
Source ClinicalTrials.gov
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Methamphetamine-negative Urine Samples | Injectable Buprenorphine (BUP-inj) | 0 | urine samples | ||
| Number of Methamphetamine-negative Urine Samples | Injectable Placebo (PBO-inj) | 0 | urine samples | ||
| Treatment Effective Score (TES) for MA-negative UDS Results | Injectable Buprenorphine (BUP-inj) | 0 | Inter-Quartile Range 0 to 0 | score on a scale | |
| Treatment Effective Score (TES) for MA-negative UDS Results | Injectable Placebo (PBO-inj) | 0 | Inter-Quartile Range 0 to 0 | score on a scale | |
| Number of Days of Methamphetamine Use During the Medication Phase | Injectable Buprenorphine (BUP-inj) | 56.0 | Standard Deviation 25.46 | days | |
| Number of Days of Methamphetamine Use During the Medication Phase | Injectable Placebo (PBO-inj) | 53.8 | Standard Deviation 27.54 | days | |
| Treatment Effective Score (TES) for Opioid Negative UDS Results | Injectable Buprenorphine (BUP-inj) | 0.62 | Inter-Quartile Range 0.5 to 0.75 | score on a scale | |
| Treatment Effective Score (TES) for Opioid Negative UDS Results | Injectable Placebo (PBO-inj) | 0.75 | Inter-Quartile Range 0.48 to 0.9 | score on a scale | |
| Number of Days of Opioid Use During the Medication Phase | Injectable Buprenorphine (BUP-inj) | 0 | Standard Deviation 0 | days | |
| Number of Days of Opioid Use During the Medication Phase | Injectable Placebo (PBO-inj) | 0 | Standard Deviation 0 | days |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Injectable Buprenorphine (BUP-inj) | 2 | |
| Overall Study | STARTED | Injectable Placebo (PBO-inj) | 4 | |
| Overall Study | COMPLETED | Injectable Buprenorphine (BUP-inj) | 1 | |
| Overall Study | COMPLETED | Injectable Placebo (PBO-inj) | 4 | |
| Overall Study | NOT COMPLETED | Injectable Buprenorphine (BUP-inj) | 1 | |
| Overall Study | NOT COMPLETED | Injectable Placebo (PBO-inj) | 0 |
Source ClinicalTrials.gov
Adverse events56
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Adverse Drug Reaction | General disorders | Injectable Buprenorphine (BUP-inj) | 1 | 5 | 1 |
| other | Adverse Drug Reaction | General disorders | Injectable Placebo (PBO-inj) | 0 | 13 | 0 |
| other | Mental Status Changes | Psychiatric disorders | Injectable Buprenorphine (BUP-inj) | 1 | 5 | 1 |
| other | Mental Status Changes | Psychiatric disorders | Injectable Placebo (PBO-inj) | 0 | 13 | 0 |
| other | Constipation | Gastrointestinal disorders | Injectable Buprenorphine (BUP-inj) | 1 | 5 | 1 |
| other | Constipation | Gastrointestinal disorders | Injectable Placebo (PBO-inj) | 3 | 13 | 3 |
| other | Dizziness | Nervous system disorders | Injectable Buprenorphine (BUP-inj) | 0 | 5 | 0 |
| other | Dizziness | Nervous system disorders | Injectable Placebo (PBO-inj) | 4 | 13 | 4 |
| other | Hyperhidrosis | Skin and subcutaneous tissue disorders | Injectable Buprenorphine (BUP-inj) | 1 | 5 | 1 |
| other | Hyperhidrosis | Skin and subcutaneous tissue disorders | Injectable Placebo (PBO-inj) | 4 | 13 | 4 |
1 to 10 of 56Source ClinicalTrials.gov
See all 56 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Injectable Buprenorphine (BUP-inj) | 0 | 5 |
| Total, all-cause mortality | Injectable Placebo (PBO-inj) | 0 | 13 |
| Total, other adverse events | Injectable Buprenorphine (BUP-inj) | 4 | 5 |
| Total, other adverse events | Injectable Placebo (PBO-inj) | 10 | 13 |
| Total, serious adverse events | Injectable Buprenorphine (BUP-inj) | 1 | 5 |
| Total, serious adverse events | Injectable Placebo (PBO-inj) | 0 | 13 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Injectable Buprenorphine (BUP-inj) vs Injectable Placebo (PBO-inj): deaths from any cause | Trial comparisons |
| Injectable Buprenorphine (BUP-inj) vs Injectable Placebo (PBO-inj): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05283304
GET https://conductscience.org/api/trials/v1/NCT05283304/events?page=2